Cataract Surgery News

NEW YORK — In his presentation at OSN New York 2019, John P. Berdahl, MD, of Vance Thompson Vision, discusses his early clinical experience implanting the Light Adjustable Lens from RxSight in cataract surgery and the excellent visual results his patients have achieved with the novel IOL.

NEW YORK — In his presentation at OSN New York 2019, Eric D. Donnenfeld, MD, discusses the latest presbyopia-correcting IOLs in development and on the market, which include the Alcon PanOptix trifocal IOL, the LensGen Juvene IOL, the Alcon/PowerVision fluid-filled IOL and the Atia Vision IOL.

NEW YORK — In her presentation at OSN New York 2019, Nicole R. Fram, MD, shares her algorithm for when to use a lasso fixation technique or when to perform an IOL exchange in cases of subluxed IOLs following cataract surgery.

NEW YORK — In his presentation at OSN New York 2019, Nathan Radcliffe, MD, discusses monitoring endothelial cell loss in glaucoma surgery patients, including those who have received the CyPass (Alcon) and Hydrus (Ivantis) devices.

ORLANDO, Fla. – Results from three vehicle-controlled phase 3 studies indicated that Dextenza was easy to insert and monitor and was well-accepted by patients.

NEW YORK — In his presentation at OSN New York 2019, William F. Wiley, MD, medical director at the Cleveland Eye Clinic, discusses how more cataract patients with astigmatism can be treated with the advent of low power toric and adjustable IOLs.

NEW YORK — In his presentation at OSN New York 2019, Mitchell P. Weikert, MD, associate professor of ophthalmology at Baylor College of Medicine, discusses current uses and potential future ways to utilize swept-source OCT in cataract surgery. – by David W. Mullin

NEW YORK — In his presentation at OSN New York 2019, John A. Hovanesian, MD, FACS, of Harvard Eye Associates in Laguna Hills, California, discusses new steroid delivery options such as Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix) and Dexycu (dexamethasone intraocular suspension 9%, EyePoint Pharmaceuticals), as well as other new steroids and NSAIDs in cataract surgery. – by David W. Mullin

NEW YORK — In her presentation at OSN New York 2019, Preeya Gupta, MD, of Duke Eye Center at Duke University, discusses why she prefers swept-source OCT for biometry measurements for cataract surgery. – by David W. Mullin

In eyes with open-angle glaucoma, endothelial cell loss after phacoemulsification combined with CyPass implantation continued for at least 5 years, while endothelial cell loss stabilized in eyes that underwent phaco without CyPass implantation after 3 months, according to a study.